Shinpoong Pharmaceutical KRX:019170KOSPI
신풍제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days3
DART filings, 7 days0
Articles tracked18since Sep 11
In Q2 2026, Shinpoong Pharmaceutical reported revenue of ₩63.9bn, up 9.0% year on year, and an operating loss of ₩8.0bn. Shinpoong Pharmaceutical (신풍제약) appeared in 3 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 23 with 4 articles. The most common catalyst was clinical & approvals (3).
Filing signals Clinical trial filing Swung to loss Screener
Shinpoong Pharmaceutical quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩63.9bn | +9.0% | −₩8.0bn margin −12.6% | −₩8.0bn |
| Q1 2026 | ₩54.5bn | -1.6% | −₩363m margin −0.7% | ₩369m |
| Q4 2025 derived | ₩58.0bn | +5.0% | ₩3.9bn margin 6.7% | ₩450m |
| Q3 2025 | ₩62.6bn | +12.2% | ₩7.2bn margin 11.5% | ₩6.4bn |
| Q2 2025 | ₩58.6bn | +4.6% | ₩4.9bn margin 8.4% | ₩2.8bn |
| Q1 2025 | ₩55.4bn | +2.6% | −₩1.8bn margin −3.2% | −₩1.3bn |
| Q4 2024 derived | ₩55.3bn | +11.4% | −₩12.1bn margin −21.9% | −₩12.7bn |
| Q3 2024 | ₩55.8bn | +13.6% | −₩165m margin −0.3% | −₩80m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Shinpoong Pharmaceutical top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6